GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Cash Flow from Operations

OncoSec Medical (FRA:ONMA) Cash Flow from Operations : €-24.10 Mil (TTM As of Jan. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Jan. 2023, OncoSec Medical's Net Income From Continuing Operations was €-6.37 Mil. Its Depreciation, Depletion and Amortization was €0.01 Mil. Its Change In Working Capital was €0.71 Mil. Its cash flow from deferred tax was €0.00 Mil. Its Cash from Discontinued Operating Activities was €0.00 Mil. Its Asset Impairment Charge was €0.00 Mil. Its Stock Based Compensation was €0.26 Mil. And its Cash Flow from Others was €-0.74 Mil. In all, OncoSec Medical's Cash Flow from Operations for the three months ended in Jan. 2023 was €-6.14 Mil.


OncoSec Medical Cash Flow from Operations Historical Data

The historical data trend for OncoSec Medical's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Cash Flow from Operations Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.88 -25.87 -28.84 -35.36 -31.59

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.85 -4.95 -6.80 -6.22 -6.14

OncoSec Medical Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

OncoSec Medical's Cash Flow from Operations for the fiscal year that ended in Jul. 2022 is calculated as:

OncoSec Medical's Cash Flow from Operations for the quarter that ended in Jan. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Jan. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-24.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSec Medical  (FRA:ONMA) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

OncoSec Medical's net income from continuing operations for the three months ended in Jan. 2023 was €-6.37 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

OncoSec Medical's depreciation, depletion and amortization for the three months ended in Jan. 2023 was €0.01 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

OncoSec Medical's change in working capital for the three months ended in Jan. 2023 was €0.71 Mil. It means OncoSec Medical's working capital increased by €0.71 Mil from Oct. 2022 to Jan. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

OncoSec Medical's cash flow from deferred tax for the three months ended in Jan. 2023 was €0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

OncoSec Medical's cash from discontinued operating Activities for the three months ended in Jan. 2023 was €0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

OncoSec Medical's asset impairment charge for the three months ended in Jan. 2023 was €0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

OncoSec Medical's stock based compensation for the three months ended in Jan. 2023 was €0.26 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

OncoSec Medical's cash flow from others for the three months ended in Jan. 2023 was €-0.74 Mil.


OncoSec Medical Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical Headlines

No Headlines